GlassScriptPhysician profile
Craig V Broussard
NPI 1609838861
$3,724.65
in general payments reported to CMS, 2019-2025
35 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $202 · 2021: $508 · 2022: $649 · 2023: $824 · 2024: $236 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $642.68 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.79 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Abbvie INC. | $466.13 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Pfizer INC. | $303.47 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $251.67 | 2019-2025 | |
| Lilly USA, LLC | $183.68 | 2020-2025 | Mounjaro, Zepbound |
| Insmed, INC. | $174.49 | 2021-2022 | |
| Philips North America LLC | $147.38 | 2021-2025 | Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $89.49 | 2019-2023 | |
| Baxter Healthcare | $85.39 | 2022 | |
| Intuitive Surgical, INC. | $67.68 | 2022-2023 | Da Vinci Surgical System |
| Janssen Pharmaceuticals, INC | $61.52 | 2019 | |
| Genentech USA, INC. | $61.47 | 2022 | |
| Amgen INC. | $60.44 | 2019-2025 | Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $59.98 | 2023-2025 | Uptravi, Opsumit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $51.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $48.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.83 | 2019-2020 | |
| Astellas Pharma US INC | $40.62 | 2021-2024 | Veozah |
| Novo Nordisk INC | $39.58 | 2019-2020 | |
| Exact Sciences Corporation | $38.14 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $33.50 | 2021 | |
| Viatris Specialty LLC | $27.51 | 2025 | Yupelri |
| Allergan, INC. | $24.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.92 | 2022 | |
| Pulmonx Corporation | $22.07 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| La Jolla Pharmaceutical Company | $19.47 | 2025 | Giapreza |
| Gilead Sciences, INC. | $17.81 | 2019 | |
| Advanced Respiratory, INC | $16.48 | 2020 | |
| Electromed, INC. | $16.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.56 | 2019 | |
| Haemonetics Corporation | $12.90 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $12.68 | 2021 | |
| Merck Sharp & Dohme LLC | $12.09 | 2019 | |
| Sumitomo Pharma America, INC. | $5.68 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.